The approval removes the binary regulatory overhang and transforms Scholar Rock into a commercial-stage company. Monitor early prescription uptake, payer coverage decisions, and the monetization value of the Priority Review Voucher. The investor call on September 14 may provide pricing and launch trajectory details.
Price Chart
Executive Summary
Scholar Rock announced FDA approval of ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy (SMA) in patients aged 2+ on SMN2-targeted therapy. This is the first and only approved muscle-targeted treatment for SMA, based on a Phase 3 study showing a 2.2-point improvement in motor function. The U.S. commercial launch is underway, and the company holds $492M in cash plus a Rare Pediatric Disease Priority Review Voucher it intends to monetize, with an additional $150M available under a debt facility.
Key Facts
- FDA approved ISEMBYLD (apitegromab-mstn) for SMA in patients ≥2 years old on SMN2-targeted therapy.
- Phase 3 SAPPHIRE study showed a 2.2-point improvement in HFMSE motor function score vs placebo (nominal p=0.0121).
- 34.2% of ISEMBYLD patients achieved ≥3-point HFMSE improvement vs 13.5% on placebo (odds ratio 3.8).
- U.S. commercial launch is underway; product available to ship in coming days.
- Company has $492M in cash, cash equivalents, and marketable securities as of June 30, 2026.
- Additional $150M available under a debt facility.
- Scholar Rock intends to monetize the Rare Pediatric Disease Priority Review Voucher awarded with the approval.
- Safety database includes >500 individuals; fractures occurred in 9% of ISEMBYLD patients vs 2% on placebo.
- ~6,600 children and adults with SMA in the U.S. are receiving an SMN2-targeted treatment (addressable population).
Financial Impact
FDA approval of first-in-class SMA therapy unlocks a new revenue stream targeting ~6,600 U.S. patients; company has $492M cash plus $150M debt facility and a monetizable Priority Review Voucher.
Risk Factors
- Commercial execution risk in a rare disease market with established SMN-targeted therapies.
- Fracture safety signal (9% vs 2% on placebo) may limit adoption in certain patient populations.
- Dependence on third-party manufacturing and supply chain for a new biologic launch.
- Pricing and reimbursement negotiations with ~50% government payer mix could pressure margins.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-107273 |
| Document: tm2625362d1_ex99-2.htm | 0001104659-26-107273 |
| Document: tm2625362d1_8k.htm | 0001104659-26-107273 |
| Document: 0001104659-26-107273-index-headers.html | 0001104659-26-107273 |
| Document: 0001104659-26-107273-index.html | 0001104659-26-107273 |
| Document: 0001104659-26-107273.txt | 0001104659-26-107273 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 5w ago | 8-K | $50.00 $49.49 | ▼ −1.03% | ▼ −1.36% | $41.61 (−16.78%) |
Sep 14, 2026 6w ago | 8-K | $51.85 $50.00 | ▼ −3.57% | ▼ −3.11% | $41.61 (−19.75%) |
Aug 6, 2026 11w ago | 8-K | $52.64 $52.92 | ▲ +0.53% | ▼ −0.08% | $41.61 (−20.95%) |
Jul 6, 2026 15w ago | Insider Cluster | $56.56 $56.03 | ▼ −0.94% | ▼ −0.63% | $41.61 (−26.43%) |
Jun 11, 2026 19w ago | Institutional Cluster | $44.69 $44.18 | ▲ +1.14% | ▲ +1.68% | $41.61 (+6.89%) |
May 7, 2026 24w ago | 8-K | $46.45 $48.39 | ▲ +4.18% | ▲ +3.35% | $41.61 (−10.42%) |
Apr 16, 2026 27w ago | Insider Cluster | $50.00 $49.96 | ▲ +0.08% | ▲ +1.29% | $41.61 (+16.78%) |
Apr 16, 2026 27w ago | Insider Cluster | $50.00 $49.96 | ▲ +0.08% | ▲ +1.29% | $41.61 (+16.78%) |
Mar 27, 2026 30w ago | Institutional Cluster | $42.60 $43.08 | ▲ +1.13% | ▲ +1.48% | $41.61 (−2.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers